Sun Pharma: Time to book profit?
While the specialty pipeline is healthy and one of the drugs under review can potentially get launched in FY25, the growth outlook for FY25 appears dull
Stay updated with breaking news from Sun Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
While the specialty pipeline is healthy and one of the drugs under review can potentially get launched in FY25, the growth outlook for FY25 appears dull
In Thursday's trading session on the BSE, shares of Sun Pharmaceutical Industries declined by 5%, reaching the day's low of Rs 1,467. This drop occurred despite the company reporting a 34% year-on-year (YoY) increase in its Q4 profit to Rs 2,654.6 crore, with revenue rising by 10.1% YoY to Rs. 11,813 crore in Q4FY24.
GRSE, Elgi Rubber Co, Excel Realty N Infra, PG Electroplast and Cochin Shipyard, hit their fresh 52-week highs at 10:54AM.
(This story has not been edited by THE WEEK and is auto-generated from a PTI
Indian equity indices were trading in the green on Thursday after a flat start. At 9:40 a.m., Sensex was up 251 points or 0.34 per cent, at 74,472 points and Nifty was up 76 points or 0.34 per cent, at 22,674 points.Midcap and smallcap stocks ...